Biodesix posts higher than expected earnings, deeper losses

BOULDER — Biodesix Inc. (Nasdaq: BDSX) had a mixed period in the first quarter of 2021, beating analyst estimates on its earnings but posting a deeper loss than expected.

The Boulder developer of lung cancer tests reported revenues of $28.9 million and a loss of 26 cents per share, beating consensus estimates by $2.67 million and missing by 9 cents, respectively, according to data from finance site Seeking Alpha.

Approximately $23.2 million of that revenue came from the company’s COVID-19 testing and processing offerings, amounting to an 8% increase in that segment from the final quarter of 2020.

The company also said its lung-testing revenue jumped 8% quarter-over-quarter to reach $4 million for the period, along with saying that a 72-hour blood test for genetic markers in lung-cancer patients is expected to become available to doctors in the first half of next year.

© 2021 BizWest Media LLC

BOULDER — Biodesix Inc. (Nasdaq: BDSX) had a mixed period in the first quarter of 2021, beating analyst estimates on its earnings but posting a deeper loss than expected.

The Boulder developer of lung cancer tests reported revenues of $28.9 million and a loss of 26 cents per share, beating consensus estimates by $2.67 million and missing by 9 cents, respectively, according to data from finance site Seeking Alpha.

Approximately $23.2 million of that revenue came from the company’s COVID-19 testing and processing offerings, amounting to an 8% increase in that segment from the final quarter of 2020.

The company also said its lung-testing revenue jumped 8% quarter-over-quarter to reach $4 million for the period, along with saying that a 72-hour blood test for genetic markers in lung-cancer patients is expected to become available to doctors in the first half of next year.

© 2021 BizWest Media LLC